Shandong Boan Biotechnology Reports 8.4% Rise in Revenue to RMB393.4 Million and Net Profit of RMB20.5 Million for H1 2025
Shandong Boan Biotechnology Co. Ltd. reported revenue of RMB393.4 million for the six months ended 30 June 2025, compared to RMB362.9 million for the same period in 2024, an increase of RMB30.5 million or 8.4%. The company attributed the rise primarily to a 15.9% growth in sales of Boyounuo, Boyoubei, and Boluojia, which reached RMB385.3 million. Net profit for the period was RMB20.5 million. This marks the company's third consecutive reporting period with a positive profit contribution. The cost of sales for the period was RMB110.8 million, representing 28.2% of total revenue, compared to 22.1% for the same period in 2024. The increase in cost ratio was mainly due to a decrease in high-margin licensing revenue. Looking ahead, Shandong Boan Biotechnology expects continued growth in revenue and profit with the planned launch of more than three new products in the next two years. The company stated it is enhancing its development potential and market competitiveness through ongoing innovation and scientific management, and is advancing digital transformation initiatives by integrating digital analysis, automation, and AI technologies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.